Announcement PDF ASX Announcement 4 December 2023 Research Agreement Executed with IFF • Microba has signed a research agreement with IFF as part of an ongoing multistage research program between the parties to develop novel microbiome-based treatments for multiple forms of allergy • The research agreement relates to a discovery program involving the isolation of strains from key species identified for the treatment of allergies using Microba’s data driven therapeutics platform • This is the second executed agreement between Microba and IFF since the initial research agreement was executed between the parties on 9 November 2021, and marks the start of the second stage of the multistage research project contemplated in the Initial Agreement Microba Life Sciences Limited (ASX: MAP) (“Microba”) is pleased to announce that it has executed a research agreement (Research Agreement) with International N&H Denmark ApS, a wholly-owned subsidiary of New York Stock Exchange listed IFF (NYSE: IFF) which sets out the terms and conditions of the second stage of the research project contemplated by the Initial Agreement (defined below) between the parties. IFF is an industry leader in food, beverage, bioscience and health sectors with a global footprint and extensive portfolio. The announcement of the Research Agreement marks the second agreement between Microba and IFF, which is a follow up to the initial research services agreement executed on 9 November 2021 (Initial Agreement), and referenced in Microba’s ASX announcement, dated 4 July 2022. Under the Initial Agreement, for Stage 1, Microba completed the identification of lead species from which IFF was entitled to select under the Initial Agreement (the Project Species). IFF has now selected a number of Project Species to move forward into Stage 2 (Selected Project Species). The overarching goal of Stage 2 under the terms of the Research Agreement is the successful isolation of strains from the Selected Project Species for IFF and characterisation of those strains. Under the Research Agreement, IFF has an exclusive option to license strains for development and 1commercialization. The Research Agreement commences on the execution date, 4 December 2023, and, subject to earlier termination, shall end upon provision of the final report, to be issued by Microba to IFF, anticipated in or around October 2024. The Research Agreement has no conditions that need to be satisfied prior to commencement. IFF can terminate the Research Agreement for convenience upon 30 days prior written notice and either party can terminate the Research Agreement for cause. Upon any termination of the Research Agreement for any reason, all rights and licenses granted to IFF under the Research Agreement and/or under the Initial Agreement shall revert to Microba. As compensation, over the term of the Research Agreement, IFF shall pay Microba approximately AUD $924,150. Further, there may be a future stage of the Research Agreement which may result in the licensing of project strains to IFF and consequential royalty payments to Microba. Microba’s Chief Executive Officer, Dr Luke Reid said, “We are excited to continue our partnership with IFF with a view to creating efficacious treatments for allergy sufferers. This program strongly aligns with Microba’s mission of improving human health, and we are delighted to partner with IFF as a leader in the field to achieve this goal”. This announcement has been authorised for release by the Board of Directors of Microba. Microba Life Sciences Ltd ABN 82 617 096 652 Level 10, 324 Queen Street, Brisbane QLD 4000 Australia T: 1300 974 621 E: investor@microba.com W: microba.com ASX Announcement 4 December 2023 For further information, please contact: Dr Luke Reid Chief Executive Officer E: Luke.Reid@microba.com For more information visit: www.microba.com Investor / Media Relations E: investor@microba.com W: https://ir.microba.com/ Join our Investor Mailing List About Microba Life Sciences Limited Microba Life Sciences is a precision microbiome company driven to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions. About International Flavors & Fragrances Inc. (IFF) At IFF (NYSE: IFF), an industry leader in food, beverage, health, biosciences and scent, science and creativity meet to create essential solutions for a better world – from global icons to unexpected innovations and experiences. With the beauty of art and the precision of science, we are an international collective of thinkers who partners with customers to bring scents, tastes, experiences, ingredients and solutions for products the world craves. Together, we will do more good for people and planet. Learn more at iff.com Disclaimer Forward looking statements This document contains certain "forward-looking statements". The words "expect", "anticipate", "estimate", "intend", "believe", "guidance", "should", "could", "may", "will", "predict", "plan" and other similar expressions are intended to identify forward-looking statements. Indications of, and guidance on, future earnings and financial position and performance are also forward-looking statements. Forward-looking statements, opinions and estimates provided in this document are based on assumptions and contingencies that are subject to change without notice and involve known and unknown risks and uncertainties and other factors that are beyond the control of Microba, its directors and management. This includes statements about market and industry trends, which are based on interpretations of current market conditions. Forward-looking statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. Actual results, performance or achievements may differ materially from those expressed or implied in such statements and any projections and assumptions on which these statements are based. These statements may assume the success of Microba’s business strategies. The success of any of those strategies will be realised in the period for which the forward-looking statement may have been prepared or otherwise. Readers are cautioned not to place undue reliance on forward-looking statements and except as required by law or regulation, none of Microba, its representatives or advisers assumes any obligation to update these forward-looking statements. No representation or warranty, express or implied, is made as to the accuracy, likelihood of achievement or reasonableness of any forecasts, prospects, returns or statements in relation to future matters contained in this document. The forward-looking statements are based on information available to Microba as at the date of this document. Except as required by law or regulation (including the ASX Listing Rules), none of Microba, its representatives or advisers undertakes any obligation to provide any additional or updated information whether as a result of a change in expectations or assumptions, new information, future events or results or otherwise. Indications of, and guidance or outlook on, future earnings or financial position or performance are also forward-looking statements. Microba encourages all current investors to go paperless by registering their details with the designated registry service provider, Automic Group. Microba Life Sciences Ltd ABN 82 617 096 652 Level 10, 324 Queen Street, Brisbane QLD 4000 Australia T: 1300 974 621 E: investor@microba.com W: microba.com